ICU Medical, Inc. Q1 2026 Earnings Recap

ICU Medical's shares jumped 5.7% post-earnings, reflecting investor approval of steady organic growth in key businesses and improving margins despite ongoing portfolio adjustments and FDA-related delays in new pump hardware approvals.

Key Takeaways

• Q1 revenue was $526 million, with 1% organic growth despite a 12% reported decline due to deconsolidation of the IV Solutions joint venture.
• Consumables revenue grew 2% organically, while IV Systems posted stronger 6% organic growth, including record pump sales and robust capital equipment demand.
• Vital Care revenue declined 14% organically, mainly driven by discontinuation of certain SKUs and portfolio rationalization; near-term organic revenue expected to be flat to slightly down.
• Gross margins improved sequentially to above 41%, driven by favorable product mix in infusion businesses.
• FDA has raised testing requirements for new Medfusion and CADD pump hardware, delaying launches but not indicating product issues; management prioritizes completion of expanded testing.